Furthermore, LX treatment leads to reduced phosphorylation of VEGFR and ephrin family receptor tyrosine kinases, thereby inhibiting the angiogenic functions associated with Kaposi’s sarcoma [218]. Here, KDR is linked to Kaposi's sarcoma.